552295-33-7

Basic information

• Product Name: Thieno[3,2-d]pyrimidin-4-amine, 6-bromo-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-
• CAS NO: 552295-33-7
• Molecular Formula: C19H12BrClFN3OS
• Molecular Weight: 464.745
• Mol File: 552295-33-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Thieno[3,2-d]pyrimidin-4-amine, 6-bromo-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Thieno[3,2-d]pyrimidin-4-amine, 6-bromo-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-(552295-33-7)
• EPA Substance Registry System: Thieno[3,2-d]pyrimidin-4-amine, 6-bromo-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-(552295-33-7)

Safety Data

• Hazardous Substances Data: 552295-33-7(Hazardous Substances Data)

Upstream product

• 443882-99-3 3-chloro-4-(3-fluorobenzyloxy)nitrobenzene 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 619-08-9 2-chloro-4-nitrophenol 
• 16269-66-2 4-chlorothieno[3,2-d]pyrimidine 
• 16234-10-9 3H-thieno[3,2-d]pyrimidin-4-one 
• 16285-69-1 3-(formylamino)-2-thiophenecarboxylic acid methyl ester 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 225385-03-5 6-bromo-4-chlorothiopheno[3,2-D]pyrimidine 
• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 

Downstream Products

• 1157899-25-6 C₃₄H₃₅ClFN₅O₇S₂ 
• 1157884-34-8 C₃₁H₂₉ClFN₅O₅S 
• 1157887-27-8 C₃₅H₃₇ClFN₅O₅S 
• 1157889-42-3 C₃₄H₃₅ClFN₅O₅S 
• 1157892-48-2 C₃₅H₃₅ClFN₅O₅S 
• 833473-58-8 C₃₅H₃₅ClFN₅O₆S 
• 1157895-61-8 C₃₅H₃₆ClFN₆O₅S 
• 1135150-86-5 C₂₄H₁₅ClFN₃O₃S 
• 1135150-95-6 C₂₈H₂₄ClFN₄O₃S 
• 1135150-88-7 C₂₄H₁₅ClFN₃O₂S₂ 
• 1135150-87-6 C₂₄H₁₅ClFN₃O₃S 
• 1135150-70-7 C₂₃H₁₅ClFN₃OS₂ 
• 1135150-63-8 C₂₃H₁₅ClFN₃O₂S 

Relevant articles and documents

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

PROTOZOAN PARASITE GROWTH INHIBITORS

Compounds and methods for inhibiting growth of a protozoan parasite. Methods of treating a protozoan parasite infection in a subject by administering a therapeutically effective amount of a compound as disclosed herein. The compounds and methods can be us

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors

Two new series of potent and selective dual EGFR/ErbB-2 kinase inhibitors derived from novel thienopyrimidine cores have been identified. Isomeric thienopyrimidine cores were evaluated as isosteres for a 4-anilinoquinazoline core and several analogs conta